F10 and cancer: According to a recent clinical practice guideline, high-risk cancer outpatients can receive thromboprophylaxis with a factor Xa inhibitor or LMWH, in the absence of major risk factors for bleeding.30 The high cost and the pain of daily LMWH injections was avoided with the factor Xa inhibitor regimen.